At What Age Can You Start Puberty Blockers? How the Timing Is Decided

Key Takeaways
At what age can you start puberty blockers? Guidelines tie the start to a stage of development: the first physical signs of puberty, called Tanner stage 2.
The World Professional Association for Transgender Health and the Endocrine Society both recommend against this medication before puberty begins.
In a study of 63 U.S. youth starting treatment, average ages were 11.0 (designated female at birth) and 12.1 (designated male at birth).
Hormone therapy is a separate, later decision.
Puberty blockers and puberty-pausing medication are two names for one treatment, and this page uses the second.
The short answer
Puberty blockers are started based on a young person's stage of puberty rather than a set birthday. Clinical guidelines say treatment can be considered once puberty has begun, at Tanner stage 2, after assessment by a clinical team and with parental consent. In two U.S. studies, average or median starting ages were about 11 to 12.
At TransHealthHub, we explain this timing so families can follow clinic conversations. Our page on Tanner stages describes each stage.
Why puberty stage matters more than age
Guidelines tie the start of treatment to the body's own timeline. Tanner staging describes five stages, from before puberty (stage 1) to adult maturity (stage 5).
"The adolescent has reached Tanner stage 2 of puberty for pubertal suppression to be initiated," the World Professional Association for Transgender Health said in its 2022 standards of care. The document says this medication is not recommended before that point because the experience of physical puberty may be critical for further gender identity development for some adolescents. It adds that puberty timing varies with sex assigned at birth, genetics, and nutrition.
The Endocrine Society's guideline similarly suggests clinicians begin treatment after young people first exhibit physical changes of puberty, and it recommends against this medication or hormone treatment in prepubertal children.
When young people actually start
Two U.S. studies put average or median starting ages around 11 to 12.
Study | Who was studied | Age or stage at start |
Lee et al., 2020 | 63 youth at four U.S. gender centers | Average 11.0 (designated female at birth) and 12.1 (designated male at birth); all at Tanner stage 2 or 3 |
Roy et al., 2024 | 19 youth on this medication alone at one Colorado center | Median age 12 |
Hughes et al., 2025 | 5,155,282 insured adolescents ages 8 to 17 | Slightly higher rates before age 14 among those assigned female at birth |
Janet Lee and colleagues reported in the Journal of the Endocrine Society that 63.5 percent of participants were at Tanner stage 2 and 36.5 percent at Tanner stage 3 as they began treatment, a small clinic-based sample that is not nationally representative.
Landon Hughes and colleagues, in JAMA Pediatrics in 2025, said the higher rates at younger ages among adolescents assigned female at birth align with their earlier onset of puberty.
What has to happen before treatment starts
Reaching Tanner stage 2 makes a young person eligible to be considered but does not start treatment by itself. Kraschel and colleagues said in Cell Reports Medicine in 2022 that guidelines highlight a parent's consent and the minor's own assent before any medical care begins.
The American Academy of Pediatrics notes these medicines have been used to delay puberty since the 1980s for central precocious puberty, a condition in which puberty starts unusually early. "Pubertal suppression is not without risks," its 2018 policy statement said, including stress from delaying puberty beyond one's peers. Our guide to bone density covers physical monitoring.
Hormones are a later, separate decision
Starting puberty-pausing medication does not set a date for hormone therapy. The Endocrine Society recommends hormone treatment only after a team confirms persistence and the capacity to give informed consent, "which most adolescents have by age 16 years." Hughes and colleagues found no insured adolescents younger than 12 received a hormone prescription. Our page on how long this medication is used explains what comes next.
What U.S. medical societies say
The American Medical Association, American Academy of Pediatrics, American Psychological Association, and the Endocrine Society regard this care as evidence-based and medically necessary, and oppose government interference in these decisions.
Some reviews have questioned how certain the evidence is. The Cass Review in the United Kingdom and a 2025 U.S. Department of Health and Human Services report rated parts of the pediatric evidence as low certainty. A low rating signals open questions; by itself, it does not show that the care causes harm.
What guidelines allow and what state law permits can differ. The KFF policy tracker counts 27 states with laws or policies limiting youth access to this care as of September 29, 2026, with 25 bans in place. In June 2025, the Supreme Court upheld Tennessee's ban in United States v. Skrmetti.
Frequently asked questions
Is there a minimum age for this medication? Guidelines set a minimum stage, Tanner stage 2, because puberty begins at different ages.
Can a child take this medication before puberty? Guidelines recommend against it. Before puberty, support is social and psychological.
Does an earlier start mean earlier hormones? Not necessarily. Hormone therapy is a separate decision tied to the capacity to consent.
Further Reading and Resources
Coleman et al., International Journal of Transgender Health (2022): Standards of Care, version 8
Endocrine Society (2017): clinical practice guideline
Lee et al., Journal of the Endocrine Society (2020): baseline study
Roy et al., Journal of the Endocrine Society (2024): bone density study
Hughes et al., JAMA Pediatrics (2025): national claims analysis
American Academy of Pediatrics (2018): policy statement
KFF (2026): state policy tracker
TransHealthHub: guide to puberty-pausing medication
This page addresses a health topic and reflects the evidence as of October 2026. It is not medical advice. Decisions about a young person's care belong to that young person, their family, and their clinicians.



Comments